Dengue has expanded dramatically over the past several decades, with the four dengue virus serotypes (DENV-1–4) now co-circulating in most dengue-endemic regions.¹ A safe and efficacious vaccine will be a crucial element of comprehensive global prevention and control. In The Lancet Infectious Diseases, Xavier Sáez-Llorens and colleagues² report 18-month interim results from a phase 2 trial of a live attenuated tetravalent dengue vaccine candidate, TDV (Takeda, Osaka, Japan). TDV was administered in either one or two doses separated by 3 or 12 months in 1800 participants aged 2–17 years in three dengue-endemic countries: Dominican Republic, Panama, and Philippines.

中文翻译：

---

令人鼓舞的结果，但对于登革热疫苗仍然存在疑问

在过去的几十年中，登革热已经急剧扩展，现在四种登革热病毒血清型（DENV-1–4）在大多数登革热流行地区共同流行。¹安全有效的疫苗将是全球全面预防和控制的关键要素。在《柳叶刀传染病》中，XavierSáez-Llorens及其同事²报告了减毒的四价登革热活疫苗候选疫苗TDV（竹田，大阪，日本）的2期试验的18个月中期结果。在三个登革热流行国家（多米尼加共和国，巴拿马和菲律宾）的1800名2-17岁的1800名参与者中，分别以一剂或两剂3或12个月的间隔分别施用TDV。